当前位置:首页 - 行情中心 - 安旭生物(688075) - 财务分析 - 现金流量表

安旭生物

(688075)

  

流通市值:49.88亿  总市值:49.88亿
流通股本:1.27亿   总股本:1.27亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金255,767,375.25103,961,347.43529,593,010.82361,389,976.8
  收到的税费返还19,923,566.088,704,418.8761,271,458.0535,672,840.93
  收到其他与经营活动有关的现金19,199,858.2814,855,431.9131,612,013.8921,732,155.15
  经营活动现金流入小计294,890,799.61127,521,198.21622,476,482.76418,794,972.88
  购买商品、接受劳务支付的现金156,274,963.4366,941,915.16324,711,771.82217,629,597.3
  支付给职工以及为职工支付的现金78,669,055.442,298,975.77108,223,493.18120,099,419.46
  支付的各项税费27,374,879.9617,711,780.2121,591,452.0727,444,081.78
  支付其他与经营活动有关的现金29,053,349.2911,667,309.0892,856,538.4229,360,931.52
  经营活动现金流出小计291,372,248.08138,619,980.22547,383,255.49394,534,030.06
  经营活动产生的现金流量净额平衡项目0000.01
  经营活动产生的现金流量净额3,518,551.53-11,098,782.0175,093,227.2724,260,942.83
二、投资活动产生的现金流量:
  收回投资收到的现金5,718,959,380.452,957,353,620.097,722,545,5005,367,080,628.3
  取得投资收益收到的现金21,585,014.816,492,703.74143,369,469.6365,848,917.75
  处置固定资产、无形资产和其他长期资产收回的现金净额--7,795,364.8120,015
  收到的其他与投资活动有关的现金--20,010,312.43-
  投资活动现金流入小计5,740,544,395.252,973,846,323.837,893,720,646.875,432,949,561.05
  购建固定资产、无形资产和其他长期资产支付的现金36,787,63316,950,520107,112,789.4457,797,311.63
  投资支付的现金5,947,194,765.332,977,598,786.047,619,776,616.665,404,184,459.86
  支付其他与投资活动有关的现金-358,910-70,074,000
  投资活动现金流出小计5,983,982,398.332,994,908,216.047,726,889,406.15,532,055,771.49
  投资活动产生的现金流量净额-243,438,003.08-21,061,892.21166,831,240.77-99,106,210.44
三、筹资活动产生的现金流量:
  偿还债务支付的现金--2,720,0002,000,000
  分配股利、利润或偿付利息支付的现金--101,696,048.7848,885,921.92
  支付其他与筹资活动有关的现金--5,311,877.37-
  筹资活动现金流出平衡项目--00
  筹资活动现金流出小计--109,727,926.1550,885,921.92
  筹资活动产生的现金流量净额平衡项目--00
  筹资活动产生的现金流量净额---109,727,926.15-50,885,921.92
四、汇率变动对现金及现金等价物的影响684,577.43328,899.8718,110,297.51-1,228,204.91
五、现金及现金等价物净增加额-239,234,874.12-31,831,774.35150,306,839.4-126,959,394.44
  加:期初现金及现金等价物余额458,283,678.15458,283,678.15307,976,838.75307,976,838.75
  期末现金及现金等价物余额219,048,804.03426,451,903.8458,283,678.15181,017,444.31
补充资料:
  净利润59,184,712.24-192,236,967.64-
  资产减值准备--12,777,723.36-
  固定资产和投资性房地产折旧23,156,710.62-44,319,063.77-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧23,156,710.62-44,319,063.77-
  无形资产摊销2,271,400.74-3,949,125.3-
  长期待摊费用摊销3,081,562.54-5,928,928.1-
  处置固定资产、无形资产和其他长期资产的损失-131,398.95--4,610,768.06-
  固定资产报废损失---144,995.35-
  公允价值变动损失-22,444,815.69--63,426,961.5-
  财务费用9,857,347.94--13,736,801.1-
  投资损失-59,702,962.11--118,212,228.95-
  递延所得税691,825.62-5,638,747.14-
  其中:递延所得税资产减少-1,645,731.09-3,291,531.26-
    递延所得税负债增加2,337,556.71-2,347,215.88-
  存货的减少11,535,381.68-42,186,757.96-
  经营性应收项目的减少9,151,444.76-12,010,329-
  经营性应付项目的增加-33,396,636.02--60,760,599.24-
  现金的期末余额219,048,804.03-458,283,678.15-
  减:现金的期初余额458,283,678.15-307,976,838.75-
  现金及现金等价物的净增加额-239,234,874.12-150,306,839.4-
公告日期2025-08-202025-04-302025-04-302024-10-31
审计意见(境内)标准无保留意见
TOP↑